Cutaneous Leukocytoclastic Vasculitis Induction Following ChAdOx1 nCoV-19 Vaccine

The coronavirus disease 2019 (COVID-19) pandemic is an unprecedented event, and in order to control its spread and minimize its damages, all efforts are immediately mobilized. Mass vaccination is considered a promising solution to combat this universal issue. However, given the urgent need for vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahrigharahkoshan, Shaghayegh, Gagnon, Louis-Philippe, Mathieu, Steve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609955/
https://www.ncbi.nlm.nih.gov/pubmed/34853744
http://dx.doi.org/10.7759/cureus.19005
Descripción
Sumario:The coronavirus disease 2019 (COVID-19) pandemic is an unprecedented event, and in order to control its spread and minimize its damages, all efforts are immediately mobilized. Mass vaccination is considered a promising solution to combat this universal issue. However, given the urgent need for vaccine production, some of the side effects may not have been presented during trials and will only appear during the mass vaccination. Limited vasculitis cases have been reported so far following vaccination against COVID-19. We present a case of cutaneous leukocytoclastic vasculitis (LCV) induced following the first dose of the ChAdOx1 nCoV-19 vaccine in an otherwise healthy individual.

Ejemplares similares